Patient Centricity
Mutual benefit: Patient centricity in clinical trials
Uli Broedl and Bronwyn Lewis share what they learnt from a successful patient organization collaboration on clinical trial design.
Search
288 Result(s)
April 13, 2021
Phase 2 Clinical Testing in NASH and Obesity
Article
Decentralized Clinical Trials (DCTs)
Pulmonary Fibrosis
Facts about the INPULSIS™ trials
Media backgrounder
Depression
Why today’s depression trials demand smart new approaches
Dr. Vikas Mohan Sharma discusses the unmet needs in major depressive disorder and the new changes digital technology is bringing to research
Article
Taking Cancer On: Patient Podcast Episodes
Listen to our podcast episodes which feature people living with cancer and their perspectives on a range of cancer topics.
Lung Cancer
LUX-Lung 7 & 8 Trials
Interview with Prof Thomas J. Lynch
Lung Cancer
Introduction to head-to-head trials
Hear from experts Dr Kerr and Dr Melosky.
September 17, 2020
Boehringer Ingelheim and Mirati Therapeutics Announce Clinical Collaboration to Study BI 1701963, a SOS1::pan-KRAS Inhibitor in Combination with MRTX849, a KRAS G12C Selective Inhibitor
May 09, 2023
IL-11 inhibitor antibody clinical development launched
September 16, 2021
Clinical collaboration with Amgen on KRAS
July 26, 2021
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase
Human Health Innovation
“Rapid progress towards clinical candidates”
Michel Pairet, Member of the Board of Managing Directors, explains why Boehringer Ingelheim expands its commitment to fighting drug resistant infections with a new joint venture.
Clinical Studies
What are clinical trial lay summaries?
Learn what lay summaries are, how we produce them and why they are useful for patients and carers.
Lung Diseases
Targeting the vicious vortex of bronchiectasis to improve symptoms and quality of life for patients.
Dr Wiebke Sauter, Clinical Program Lead for Bronchiectasis at Boehringer Ingelheim, explores the unmet needs for people living with bronchiectasis.
Pulmonary Fibrosis
Addressing the urgent need for new treatments for people living with idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung diseases (ILDs)
Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program.
June 23, 2023
Phase II trial data shows nearly 19% weight loss in people with overweight or obesity
Gastrointestinal Cancers
Brightline-2 trial launch in biliary tract and pancreatic cancers
Find out more about the Brightline-2 trial and our commitment to people living with biliary tract and pancreatic cancers.
March 28, 2022
New spesolimab data show significant improvement in GPP flares
March 01, 2022
Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
March 16, 2020
New uncommon EGFR mutations database published featuring clinical outcomes of NSCLC patients treated with afatinib
May 26, 2020
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining empagliflozin’s effects following an acute myocardial infarction
September 10, 2020
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
Patient Centricity
Our position
Boehringer Ingelheim’s position on compassionate use of investigational medications.
Schizophrenia
GlyT1 Phase II study
Boehringer Ingelheim refocuses Gly-T1 inhibition brain research on schizophrenia